Login / Signup

Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases.

Annemarie C EggenGeke A P HospersIngeborg BosmaMiranda C A KramerAnna K L ReynersMathilde Jalving
Published in: BMC cancer (2022)
The majority of patients with melanoma brain metastases received anti-tumor treatment during the last 3 months of life. ER visits and hospitalizations occurred more often in patients on anti-tumor treatment. Further research is warranted to examine the impact of anti-tumor treatments close to death on symptom burden and care satisfaction.
Keyphrases